Findlay Park Partners LLP Sells 54,400 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Findlay Park Partners LLP sold 54,400 shares of Medpace Holdings, decreasing its stake by 11.5%, leaving it with 418,700 shares valued at approximately $127.57 million.
• Medpace's latest earnings report showed a 14.2% year-over-year increase in revenue, with an EPS of $3.10, surpassing analysts' expectations of $3.00.
• Analysts' ratings on Medpace are mixed, with two Buy ratings, nine Hold ratings, and three Sell ratings, reflecting a consensus target price of $406.60.

Findlay Park Partners LLP decreased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 11.5% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 418,700 shares of the company's stock after selling 54,400 shares during the period. Findlay Park Partners LLP owned 1.46% of Medpace worth $127,574,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in MEDP. Brooklyn Investment Group boosted its position in Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after purchasing an additional 71 shares during the period. Whittier Trust Co. boosted its holdings in shares of Medpace by 47.3% during the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after buying an additional 35 shares during the period. Colonial Trust Co SC boosted its holdings in shares of Medpace by 150.0% during the 4th quarter. Colonial Trust Co SC now owns 175 shares of the company's stock worth $58,000 after buying an additional 105 shares during the period. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Medpace in the 1st quarter valued at $60,000. Finally, Assetmark Inc. raised its holdings in Medpace by 24.9% in the 1st quarter. Assetmark Inc. now owns 216 shares of the company's stock worth $66,000 after acquiring an additional 43 shares during the period. 77.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on MEDP shares. Robert W. Baird upped their price target on shares of Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft increased their target price on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a research note on Wednesday, July 23rd. UBS Group downgraded Medpace from a "neutral" rating to a "sell" rating and lifted their price target for the stock from $300.00 to $305.00 in a research report on Tuesday, July 29th. William Blair reissued a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Finally, TD Cowen reaffirmed a "sell" rating and set a $366.00 target price (up previously from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of "Reduce" and a consensus price target of $406.60.

Medpace Stock Down 0.1%

Medpace stock traded down $0.54 on Thursday, hitting $472.94. The company's stock had a trading volume of 202,838 shares, compared to its average volume of 356,826. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $501.30. The firm has a market cap of $13.28 billion, a P/E ratio of 35.16, a price-to-earnings-growth ratio of 2.98 and a beta of 1.42. The company has a fifty day moving average price of $392.42 and a 200-day moving average price of $338.34.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 EPS for the quarter, topping analysts' consensus estimates of $3.00 by $0.10. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The company had revenue of $603.31 million during the quarter, compared to the consensus estimate of $537.70 million. During the same period last year, the firm earned $2.75 EPS. The firm's revenue for the quarter was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Activity

In other Medpace news, General Counsel Stephen P. Ewald sold 3,000 shares of Medpace stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. The trade was a 22.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Susan E. Burwig sold 7,500 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $450.14, for a total value of $3,376,050.00. Following the completion of the transaction, the vice president directly owned 57,500 shares of the company's stock, valued at approximately $25,883,050. The trade was a 11.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 115,070 shares of company stock valued at $52,085,751. 20.30% of the stock is owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.